SCHEMBL8103372

SCHEMBL8103372

COc1ccc(-c2cn3c(OC(=O)C(C)(C)C)nc4c(c3n2)CCCC4)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.43
NPC1 O15118 7/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
MAPT P10636 5/20 0.43
ALDH1A1 P00352 3/20 0.43
TP53 P04637 3/20 0.43
GAA P10253 2/20 0.43
NFKB1 P19838 1/20 0.43
GFER P55789 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
WDR5 P61964 1/20 0.41
DCTPP1 Q9H773 1/20 0.40
HRH2 P25021 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8097140 0.75 ALDH1A1 (0.42) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL8097270 0.69 GABRA1 (0.63) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL8088041 0.68 GABRA3 (0.48) GABRA1GABRA2
SCHEMBL8096753 0.66 GABRA3 (0.44) GABRA1GABRA2
SCHEMBL9954037 0.64 ELANE (0.70) RAB9ASMN1; SMN2LMNACYP1A2HSD17B10
SCHEMBL11596680 0.62 ELANE (0.73) RAB9ASMN1; SMN2LMNACYP1A2HSD17B10
SCHEMBL8102864 0.61 ALDH1A1 (0.45) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL8096793 0.61 ALDH1A1 (0.45) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL12692391 0.61 RAB9A (1.00) RAB9ANPC1SMN1; SMN2MAPTALDH1A1
SCHEMBL6075852 0.61 HRH2 (0.55) RAB9ANPC1SMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5426186-A Diagnosis, treatment of anxiety, sleep and seizure disorders, benzodiazepine overdose; enhancement of alertness NEUROGEN CORPORATION (US) 1995-06-20 US claimed
EP-0547168-A1 CERTAIN CYCLOALKYL IMIDAZOPYRIMIDINES, A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1993-06-23 EP claimed
WO-1992004351-A1 CERTAIN CYCLOALKYL IMIDAZOPYRIMIDINES, A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS NEUROGEN CORPORATION (US) 1992-03-19 WO claimed
US-6013799-A HIGHLY SELECTIVE AGONISTS, ANTAGONISTS OR INVERSE AGONISTS FOR G-AMINOBUTYRIC ACID (GABA) BRAIN RECEPTORS; USEFUL IN DIAGNOSIS/TREATMENT OF ANXIETY, SLEEP, AND SEIZURE DISORDERS, DRUG OVERDOSE, AND ALERTNESS ENHANCEMENT ALERTNESS NEUROGEN CORPORATION (US) 2000-01-11 US disclosed
US-5696260-A AGONSIT, ANTAGONIST, PRODRUG; USEFUL IN DIAGNOSIS AND TREATMENT OF ANXIETY, SLEEP, SEIZURE DISORDER, OVERDOSE WITH BENZODIAZEPINE TYPE DRUGS AND ENHANCEMENT OF ALERTNESS NEUROGEN CORPORATION (US) 1997-12-09 US disclosed
US-5426186-A Diagnosis, treatment of anxiety, sleep and seizure disorders, benzodiazepine overdose; enhancement of alertness NEUROGEN CORPORATION (US) 1995-06-20 US disclosed